Imaging

Visual versus quantitative analysis of tau-PET

Advantages of tau-PET compared to amyloid-PET

Time gap between amyloid- and tau-PET positivity in preclinical disease

Ultra-high field 7T MRI for diagnosis of early Alzheimer’s Disease

Discriminative power of a multi-PET tracer approach in primary tauopathies

APOEε4 drives tau accumulation through Aβ-dependent and Aβ-independent pathways

Decreased kidney function associated with increased plasma p-tau levels

What causes ARIA in response to Alzheimer’s disease immunotherapy?

Comparing the performance of blood-based amyloid and tau assays

Why does tau-PET not detect the earliest stages of Alzheimer’s disease?

APOEε4 drives Aβ-dependent formation of tau tangles

APOEε4 triggers early microglial activation in Alzheimer’s disease

Current and future role of tau-PET in dementia daily practice

Longitudinal clinical outcomes of tau-PET-positive individuals

Limitations of [18F]flortaucipir tau-PET imaging

Next generation tau tracers: [18F]MK-6420 vs [18F]flortaucipir